MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc

Denali Therapeutics Inc

Avatud

SektorTervishoid

21.63 7.61

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.11

Max

21.7

Põhinäitajad
By Trading Economics
Sissetulek	-1.6M -129M
Töötajad	503
EBITDA	8.9M -125M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+86.77% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-184M 3.1B
Eelmine avamishind	14.02
Eelmine sulgemishind	21.63

Uudiste sentiment

By Acuity

50%

156 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

13.355 / 16.44 Toetus ja vastupanu

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

14. apr 2026, 23:36 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

14. apr 2026, 23:24 UTC

Kuumad aktsiad

Stocks to Watch: Gloo, Broadcom, GitLab

14. apr 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

14. apr 2026, 21:32 UTC

Suurimad hinnamuutused turgudel

GitLab Shares Rise on Expanded Google Cloud Collaboration

14. apr 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

14. apr 2026, 23:34 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

14. apr 2026, 22:54 UTC

Tulu

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

14. apr 2026, 22:54 UTC

Tulu

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Targets Deal Completion Toward End of 3Q

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

14. apr 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

14. apr 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

14. apr 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

14. apr 2026, 22:14 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

14. apr 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

14. apr 2026, 22:12 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

14. apr 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

14. apr 2026, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Basic Materials Roundup: Market Talk

14. apr 2026, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 20:32 UTC

Kuumad aktsiad

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

14. apr 2026, 19:59 UTC

Omandamised, ülevõtmised, äriostud

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

14. apr 2026, 19:38 UTC

Tulu

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

14. apr 2026, 19:27 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

14. apr 2026, 19:21 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

14. apr 2026, 19:09 UTC

Omandamised, ülevõtmised, äriostud

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

14. apr 2026, 18:30 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. apr 2026, 18:30 UTC

Market Talk

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

86.77% tõus

12 kuu keskmine prognoos

Keskmine 36.27 USD 86.77%

Kõrge 42 USD

Madal 30 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

14 ratings

Osta

Hoia

Müü

Põhineb 14 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

13.355 / 16.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

156 / 348 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.